Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Non-Current Deffered Revenue data on file, last reported at -$277000.0 in Q2 2025.

• Quarterly Non-Current Deffered Revenue fell 110.24% year-over-year to -$277000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$277000.0 (down 110.24% YoY) and the FY2023 annual result came in at $48.0 million, up 15722.8% from the prior year.
• Non-Current Deffered Revenue retreated to -$277000.0 in Q2 2025, from -$134000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $252.6 million in Q2 2021 to a low of -$484000.0 in Q3 2023.
• A 5-year average of $23.2 million and a median of -$145000.0 in 2022 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue sank 158.77% — and 2023, when it jumped 62388.31%.
• Tracing LEGN's Non-Current Deffered Revenue over 5 years: stood at -$295000.0 in 2021, then advanced by 20.68% to -$234000.0 in 2022, then surged by 20596.58% to $48.0 million in 2023, then slumped by 100.9% to -$430000.0 in 2024, then surged by 35.58% to -$277000.0 in 2025.
• The last three Non-Current Deffered Revenue figures came in at -$277000.0 (Q2 2025), -$134000.0 (Q1 2025), and -$430000.0 (Q3 2024), per Business Quant data.